Lonza Group (LZAGY)
(Delayed Data from OTC)
$58.32 USD
+0.33 (0.57%)
Updated Jul 23, 2024 03:59 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Lonza Group Ag (LZAGY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$66.20 | $66.20 | $66.20 | 14.16% |
Price Target
Only one analyst offered a short-term price target of $66.20 for Lonza Group Ag. This represents an increase of 14.16% from the last closing price of $57.99.
Analyst Price Targets (1 )
Broker Rating
Lonza Group Ag currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, 10 are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 1 |
Hold | 2 | 2 | 2 | 2 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/23/2024 | Berenberg Bank | Sebastian Bray | Not Available | Strong Buy |
4/2/2024 | Not Identified | Not Identified | Hold | Hold |
3/25/2024 | Exane BNP Paribas | Gary Steventon | Not Available | Strong Buy |
3/20/2024 | William Blair | Maxwell A Smock | Strong Buy | Strong Buy |
1/29/2024 | Not Identified | Not Identified | Strong Sell | Hold |
12/11/2023 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
10/18/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 12 |
Average Target Price | $66.20 |
LT Growth Rate | 15.60% |
Industry | Medical - Products |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | NA |